Traws Pharma Inc. has announced the acquisition of certain assets from Virom, Inc. through an Asset Purchase Agreement dated September 9, 2025. The $2.35 million transaction includes the purchase of intellectual property, patents, and other assets related to a pyrrolidine antiviral compound and its associated program pipeline. The acquisition, approved by Traws Pharma's Audit Committee and Board of Directors, also incorporates a third-party license agreement and related regulatory filings.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-089564), on September 12, 2025, and is solely responsible for the information contained therein.